
Results
4
Companies which are more than 50% undervalued based on analyst price target.
4 companies
Formycon
Market Cap: €346.4m
A biotechnology company, develops biosimilar drugs in Germany and Switzerland.
FYB
€20.35
7D
1.9%
1Y
-23.5%
Heidelberg Pharma
Market Cap: €123.0m
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally.
HPHA
€2.63
7D
-0.8%
1Y
-34.4%
Darwin
Market Cap: €95.4m
Operates in the healthcare industry.
7V0
€7.95
7D
32.5%
1Y
n/a
Cantourage Group
Market Cap: €76.8m
Operates as a medical cannabis company in Europe and internationally.
HIGH
€6.22
7D
-0.3%
1Y
14.8%